Brokers Set Expectations for VIGL FY2029 Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Equities researchers at Wedbush issued their FY2029 EPS estimates for Vigil Neuroscience in a research report issued on Thursday, March 13th. Wedbush analyst L. Chico expects that the company will post earnings of $1.40 per share for the year. Wedbush currently has a “Outperform” rating and a $13.00 price target on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share.

Several other equities research analysts also recently commented on VIGL. HC Wainwright lowered their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, March 14th. William Blair assumed coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Vigil Neuroscience presently has an average rating of “Buy” and an average target price of $16.25.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL opened at $1.97 on Monday. Vigil Neuroscience has a 52 week low of $1.49 and a 52 week high of $6.06. The company has a market capitalization of $80.53 million, a PE ratio of -0.96 and a beta of 1.82. The company has a 50 day moving average price of $2.34 and a two-hundred day moving average price of $2.76.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. abrdn plc boosted its holdings in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after buying an additional 293,461 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the period. Verition Fund Management LLC acquired a new position in Vigil Neuroscience during the third quarter worth $442,000. Walleye Capital LLC boosted its holdings in Vigil Neuroscience by 334.4% during the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in Vigil Neuroscience by 7.7% during the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after purchasing an additional 115,000 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.